RT Journal Article
SR Electronic
T1 Antiviral use and the effects of drug resistance on the transmission dynamics of influenza
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2025.03.10.25323668
DO 10.1101/2025.03.10.25323668
A1 Schuh, Lea
A1 Stilianakis, Nikolaos I.
YR 2025
UL http://medrxiv.org/content/early/2025/03/11/2025.03.10.25323668.abstract
AB The effectiveness of antivirals in mitigating influenza outbreaks depends on both their ability to reduce the number of infections and the risk of drug resistance. We extended a previously developed mathematical model to investigate the impact of mitigation strategies, including mono or combination antiviral treatment or chemoprophylaxis and vaccination, on influenza transmission dynamics. Our findings indicate that chemoprophylaxis is more effective than treatment in reducing influenza burden, except when the resistant strain has a high transmission rate, in which case chemoprophylaxis may trigger a resistance-driven secondary infection wave. Combination therapy considerably reduces resistance emergence with similar infection numbers as mono-therapy. Vaccination coverage of at least 80% is required to prevent outbreaks; otherwise, antivirals can contribute to outbreak control provided drug resistance emergence is low. This analysis could inform public health decision-making by providing guidance on effective mitigation strategies for influenza outbreaks, considering their benefits against the risk of drug resistance.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research received no specific grant from any funding agency.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThere is no original data underlying this work.